• Novo Nordisk is trading at $46.83 (-9.26%) in pre-market after announcing headline results from its ZEUS cardiovascular outcomes Phase 3 trial.
  • The trial for ziltivekimab demonstrated target engagement but did not translate into major adverse cardiovascular events (MACE) reduction, which was its primary endpoint.
  • While the outcome will not change the previously communicated 2026 operating profit outlook, it will lead to a non-cash impairment charge in Q3 2026.